Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Young-Hyuck Im 1 Article
Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
Misun Choi, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Soo Youn Cho, Eun Yoon Cho
J Pathol Transl Med. 2017;51(1):69-78.   Published online December 25, 2016
  • 9,484 View
  • 238 Download
  • 19 Citations
AbstractAbstract PDF
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) has been associated with favorable clinical outcome in breast cancer patients. However, the possibility that the prognostic significance of pCR differs among various definitions has not been established. Methods: We retrospectively evaluated the pathologic response after NAC in 353 breast cancer patients and compared the prognoses after applying the following different definitions of pCR: ypT0/is, ypT0, ypT0/is ypN0, and ypT0 ypN0. Results: pCR was significantly associated with improved distant disease-free survival (DDFS) regardless of the definition (ypT0/is, p = .002; ypT0, p = .008; ypT0/is ypN0, p < .001; ypT0 ypN0, p = .003). Presence of tumor deposits of any size in the lymph nodes (LNs; ypN ≥ 0(i+)) was associated with worse DDFS (ypT0 ypN0 vs ypT0 ypN ≥ 0(i+), p = .036 and ypT0/is ypN0 vs ypT0/is ypN ≥ 0(i+), p = .015), and presence of isolated tumor cells was associated with decreased overall survival (OS; ypT0/is ypN0 vs ypT0/is ypN0(i+), p = .013). Residual ductal carcinoma in situ regardless of LN status showed no significant difference in DDFS or OS (DDFS: ypT0 vs ypTis, p = .373 and ypT0 ypN0 vs ypTis ypN0, p = .462; OS: ypT0 vs ypTis, p = .441 and ypT0 ypN0 vs ypTis ypN0, p = .758). In subsequent analysis using ypT0/is ypN0, pCR was associated with improved DDFS and OS in triple-negative tumors (p < .001 and p = .003, respectively). Conclusions: Based on our study results, the prognosis and rate of pCR differ according to the definition of pCR and ypT0/is ypN0 might be considered a more preferable definition of pCR.


Citations to this article as recorded by  
  • Pathology after neoadjuvant treatment – How to assess residual disease
    Giuseppe Viale, Nicola Fusco
    The Breast.2022; 62: S25.     CrossRef
  • Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)
    Nicola Fusco, Antonio Rizzo, Leopoldo Costarelli, Alfredo Santinelli, Bruna Cerbelli, Cristian Scatena, Ettore Macrì, Francesca Pietribiasi, Giulia d’Amati, Anna Sapino, Isabella Castellano
    Pathologica.2022; 114(2): 104.     CrossRef
  • Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
    Matthew G. Davey, Ferdia Browne, Nicola Miller, Aoife J. Lowery, Michael J. Kerin
    BJS Open.2022;[Epub]     CrossRef
  • Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
    Lisi M. Dredze, Michael Friger, Samuel Ariad, Michael Koretz, Bertha Delgado, Ruthy Shaco-Levy, Margarita Tokar, Michael Bayme, Ravit Agassi, Maia Rosenthal, Victor Dyomin, Olga Belochitski, Shai Libson, Tamar Mizrahi, David B. Geffen
    Breast Cancer Research and Treatment.2022; 193(3): 597.     CrossRef
  • “No Ink on Tumor” in Breast-Conserving Surgery after Neoadjuvant Chemotherapy
    Giulia Atzori, Marco Gipponi, Chiara Cornacchia, Raquel Diaz, Marco Sparavigna, Maurizio Gallo, Tommaso Ruelle, Federica Murelli, Simonetta Franchelli, Francesca Depaoli, Daniele Friedman, Piero Fregatti
    Journal of Personalized Medicine.2022; 12(7): 1031.     CrossRef
  • Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer
    Carmen Herrero Vicent, Xavier Tudela, Paula Moreno Ruiz, Víctor Pedralva, Ana Jiménez Pastor, Daniel Ahicart, Silvia Rubio Novella, Isabel Meneu, Ángela Montes Albuixech, Miguel Ángel Santamaria, María Fonfria, Almudena Fuster-Matanzo, Santiago Olmos Antó
    Cancers.2022; 14(14): 3508.     CrossRef
  • Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction
    Meredith A. Jones, Warid Islam, Rozwat Faiz, Xuxin Chen, Bin Zheng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy
    Ina Jani, Ricardo R Lastra, Katherine S Brito, Chuanhong Liao, Isabel Lazo, Nita Karnik Lee, S Diane Yamada, Katherine C Kurnit
    International Journal of Gynecologic Cancer.2021; 31(6): 852.     CrossRef
  • Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
    Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu, Ai-Ping Shi
    World Journal of Clinical Cases.2021; 9(4): 919.     CrossRef
  • Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis
    Hui Liu, Liqiong Lv, Hui Gao, Ming Cheng, Tao Huang
    Computational and Mathematical Methods in Medicine.2021; 2021: 1.     CrossRef
  • Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
    K. Wimmer, M. Bolliger, Z. Bago-Horvath, G. Steger, D. Kauer-Dorner, R. Helfgott, C. Gruber, F. Moinfar, M. Mittlböck, F. Fitzal
    Annals of Surgical Oncology.2020; 27(5): 1700.     CrossRef
  • Predictive factors for omitting lymphadenectomy in patients with node‐positive breast cancer treated with neo‐adjuvant systemic therapy
    Sergi Fernandez‐Gonzalez, Catalina Falo, Maria J. Pla, Paula Verdaguer, Diana Nuñez, Anna Guma, Teresa Soler, Andrea Vethencourt, Silvia Vázquez, Maria Eulalia Fernandez‐Montoli, Miriam Campos, Sonia Pernas, Miguel Gil, Jordi Ponce, Amparo Garcia‐Tejedor
    The Breast Journal.2020; 26(5): 888.     CrossRef
  • Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
    Qian Wang, Jingjing Zhao, Xiaowei Han, Puchun Er, Xiangying Meng, Jinyan Shi, Huiru Sun, Jingyang Zhu, Li Zhu, Shikai Wu, Wencheng Zhang, Bing Sun
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer
    Rajat Bajaj, Rupal Tripathi, T. S. Sridhar, Aruna Korlimarla, Kumardeep Dutta Choudhury, Moushumi Suryavanshi, Anurag Mehta, Dinesh Chandra Doval, Elda Tagliabue
    PLOS ONE.2020; 15(11): e0242190.     CrossRef
  • Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
    Min Huang, Joyce O'Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, Peter Hu, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, Peter A. Fasch
    Cancer Research.2020; 80(24): 5427.     CrossRef
  • Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response
    G Santamaría, X Bargalló, S Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A Prat
    European Journal of Radiology.2019; 117: 132.     CrossRef
  • Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy
    Reshu Agarwal, Arun Philip, Keechilat Pavithran, Anupama Rajanbabu, Gaurav Goel, DK Vijaykumar
    Indian Journal of Cancer.2019; 56(3): 228.     CrossRef
  • Application of neoadjuvant chemotherapy in occult breast cancer
    Haisong Yang, Ling Li, Mengmeng Zhang, Shiyong Zhang, Shu Xu, Xiaoxia Ma
    Medicine.2017; 96(40): e8200.     CrossRef
  • Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer
    Kijong Yi, Kyueng-Whan Min, Young Chan Wi, Yeseul Kim, Su-Jin Shin, Min Sung Chung, Kiseok Jang, Seung Sam Paik
    Journal of Breast Cancer.2017; 20(4): 361.     CrossRef

JPTM : Journal of Pathology and Translational Medicine